Stelara biosimilars look to gain traction, helped by recent lessons from Humira

AbbVie's defense of its megablockbuster Humira may go down in the history books as the poster child for blocking biosimilar competition, but the launch of six Stelara biosimilars this year shows how competitors have learned ...